Artificial Intelligence in Rheumatology: Now and the Future Drs. Antoni Chan and Thomas Hugle discuss abstract POS0892 from EULAR 2023 in Milan, Italy. https://t.co/rftHTKY6MX @synovialjoints https://t.co/PtlKg4o18s

• https://bit.ly/3qECmiz

WATCH: JAKpot or JAKnot Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy. https://t.co/RSJX4hcMRU https://t.co/XYuOrSCxjf

• https://bit.ly/3Ntp95j

EULAR 2023 recommendation for imaging in large vessel vasculitis Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. https://t.co/o8cpSOXNy4 @bella_mehta https://t.co/aCM3yzT32e

• https://bit.ly/3qL3jRB

Report of 54 nonradiographic axial SpA pts w/ recurrent fever. Fever preceded SpA in all; age @ axSpA Dx 39.9 yrs, w/ Dx delay 9.3 yrs. Fevers 38-42°C, arthralgia 61%, myalgia 44%, arthritis 41%, GI 25%, Rash 22%. Best Rx to TNFi > IL1i, colchicine, DMARD https://t.co/muSYhZFXku https://t.co/1lUPCMyuCX

• https://bit.ly/3NnOoG1

Karolinska SARA (secretory antibodies in RA) study of 132 RA pts found salivary IgA anti-RgpB Abs signif higher in RA than (p = 0.022), & were assoc w/ disease activity (p = 0.036), but not with periodontitis or serum IgG ACPA. https://t.co/4uul4b5Fhg https://t.co/R5WVCyjc3B

• https://bit.ly/45X8sWS

RheumNow Eular 2023 Daily Recap Series - Day1 & 2 RheumNow faculty and reporters provide a daily recap of conference content coverage. https://t.co/GCDmZT5dyE https://t.co/tXV9qDmcEu

• https://bit.ly/3CHrfIF

Should we be reassured of JAK safety with new data? Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy. https://t.co/Gf4puWXkLY https://t.co/kcnpfEpnTW

• https://bit.ly/43RhQcQ

Still's Disease Abstracts at EULAR 2023 https://t.co/lb1QRcsa9G https://t.co/JIBszS7s7D

• https://bit.ly/3p1GWHh

Watch: IRAEs, Targeted Therapies and Survival Dr. Aurelie Najm discusses OP0270 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/501Rc4SPY1 https://t.co/Ifw93ICqwW

• https://bit.ly/43T3FUz

Novel drug in development, LY3361237, is a BTLA (B & T lymphocyte attenuator) agonistic antibody to treat autoimmune Dz (eg SLE) - augments immune responses by activating checkpoint inhibitory receptors (CIRs). https://t.co/3iYq9UwHww https://t.co/RwrhqRO8cm https://t.co/tl8qVIXqjc

• https://bit.ly/3N3yEGF
• https://bit.ly/3MTU5tG

Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP

• https://wb.md/43SnMSP